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Background: Recent data shows that patients with severe acute pancreatic might benefit from early intensive
therapy, enteral nutrition and timely transfer to specialized centers. The early prophylactic use of antibiotics in AP
remains controversial. The role and need for new markers in stratification of acute pancreatitis is also uncertain. This
study aims to evaluate the prognostic usefulness of adipokines in prediction of the severity and outcome of acute
pancreatitis (AP).
Methods: Prospective study was conducted in four clinical centers. The diagnosis and severity assessment of AP
was established according to the revised 2012 Atlanta classification. Adipokines, IL-6 and CRP levels were measured
at admission and on 3rd day of hospital stay and compared with the control group. The predictive accuracy of
each marker was measured by area under the receiver operating curve.
Results: Forty healthy controls and 102 patients were enrolled in to the study. Twenty seven (26.5 %) patients had
mild, 55 (53.9 %) - moderate and 20 (19.6 %) - severe AP. Only resistin (cut-off value 13.7 ng/ml) and IL-6 (cut-off
value 473.4 pg/ml) were reliable early markers of SAP. IL-6 with cut-off value of 157.0 pg/ml was a predictor of
necrosis. The peripancreatic necrosis volume of 112.5 ml was a marker of SAP and 433.0 ml cut-off value could be
used to predict the need of interventions.
Conclusions: The prognostic value of adipokines in AP is limited. Only admission resistin levels could serve as an
early predictor for SAP.
The Lithuanian Regional Ethics Committee approved the study protocol (permission No. L-12-02/1/2/3/4) and all
the patients and the control group provided written informed consent.
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Acute pancreatitis (AP) is a disease with highly variable
clinical course. Majority of patients have mild and self-
limiting disease, but the mortality rate of patients with se-
vere and complicated forms can reach up to 30 % [1–4].
Non-complicated forms of AP can be treated in smaller re-
gional hospitals, but the patients with the severe course of
AP should be timely transferred to the high volume centers
[5]. It has been reported that hospitals treating higher
number of AP cases have better clinical outcomes [6, 7]. A
number of predictive markers and scoring systems were
introduced in to clinical practice for early prediction of
severe AP (SAP), local or systemic complications and mor-
tality. The importance of the early prognosis of the course
of the disease was shown in some studies. Data revealed
that very low mortality rates are associated with early rec-
ognition of SAP patients and adequate intensive therapy
[8]. Enteral nutrition, if started at least within 48 h after ad-
mission, can reduce the incidence of complications and
can contribute to an increased rate of survival [5]. The
early prophylactic use of antibiotics in AP remains con-
troversial. American College of Gastroenterology and
IAP/APA guidelines both recommend against antibiotic
use [9–11]. But according to the newest Japanese guide-
lines for the management of acute pancreatitis based on
recent meta-analysis, the prophylactic administration of
antibiotics in SAP and necrotizing pancreatitis may im-
prove the prognosis, if carried out within 72 h after onset
of AP [5, 12, 13]. So, the discussion about the early use of
antibiotics is still open, because it may turn out that they
are useful for selective patient group.
The adequate management of the AP patients within
first 2 3 days could be of vital importance and determine
the future prognosis. Based on the revised Atlanta 2012
classification moderately severe acute pancreatitis is
defined by the presence of transient organ failure, local
complications or exacerbation of co-morbid disease.
Severe acute pancreatitis is defined by persistent organ
failure, that is, organ failure >48 h. Thus in the real clin-
ical setting it is very difficult to determine the severity of
the disease within the first hours after admission, be-
cause it is not known whether the patient would have
transient, persistent organ failure or no organ failure at
all. It is suggested that initially the patient should be
classified and treated as potentially having SAP, if he/she
does not have mild pancreatitis on admission [14]. How-
ever, this is only possible in specialized, high volume
centers, whereas smaller regional hospitals could face
certain difficulties implementing this strategy.
Currently prognosis of the AP is largely based on clin-
ical scores, such as APACHE II, BISAP and many others.
The main problem is that all of them are multifactorial
and rather uncomfortable for everyday use, so there is a
great stimulus for seeking new accurate single prognosticmarker. C-reactive protein (CRP) is the most widely
explored and described single predictor for disease sever-
ity and pancreatic necrosis. However, its concentration
reaches a peak on 3rd day of the disease, so it has a great-
est prognostic value approximately 48 h after the onset of
the symptoms. IL-6 is also introduced in clinical practice
and is approved as a reliable prognostic marker in many
countries.
The predictive value of adipokines, such as leptin, adi-
ponectin, resistin and visfatin, is less explored. Adipokines
are cytokines produced in white adipose tissue as well as
in peripancreatic fat and involved in inflammatory re-
sponse. Increase of fatty tissue due to obesity is associated
with the amplified systemic inflammatory response in AP;
furthermore it can be used as a prognostic factor for mor-
tality, local, systemic complications and severity of AP
[15]. Peripancreatic fat necrosis in acute pancreatitis is
associated with the development of SAP, multiple organ
failure and mortality [16, 17]. It is hypothesized that
peripancreatic necrosis can cause the massive release of
adipokines into the bloodstream, so adipokines can serve
as predictors of clinical course and complications of acute
pancreatitis.
The significant differences of resistin, visfatin, leptin and
adiponectin concentrations between mild AP (MAP) and
SAP patients were found in some older studies, but all of
them were very different in their methodology, diagnostic
criteria, classification and evaluation of AP [18–24]. Fur-
thermore, in 2012 the Atlanta classification of AP was
revisited and a new form of moderately severe AP was
identified [14]. Therefore the criteria of SAP became more
stringent and the cut off values for adipokines, as well as
for CRP and IL-6 must be recalculated.
Methods
Study design and patient population
Our study was conducted in four Lithuanian hospitals
during the period between April 2012 and March 2015.
The Regional Ethics Committee approved the study proto-
col (permission No. L-12-02/1/2/3/4) and all the patients
and the control group provided written informed consent.
The diagnosis of AP was established according to the
revised Atlanta 2012 classification and based on the
presence of at least two of the three following features:
abdominal pain characteristic of acute pancreatitis,
serum amylase level ≥3 times up the upper limit of nor-
mal and characteristic findings of AP on abdominal
computerized tomography scan.
All patients admitted to the hospitals with a diagnosis
of acute pancreatitis and onsets of the symptoms within
last 72 h were included in this study. Pregnant women,
patients with the history of necrotizing pancreatitis and
underlying chronic pancreatitis were excluded from
this study.
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index (BMI), presence of organ failure and local compli-
cations, interventions, in-hospital mortality and length
of hospital stay were recorded.
According to the revisited Atlanta classification, based
on organ failure, all the AP patients retrospectively were
classified as mild, moderate or severe AP cases.
Percutaneus drainage, endoscopic, laparoscopic and
open necrosectomy were classified as interventions. No
interventions were performed in the conservative manage-
ment group. Indications for interventions were clinical
suspicion of or radiologically proven infected pancreatic
or peripancreatic necrosis with clinical deterioration or
ongoing organ failure several weeks after the onset of the
AP, preferably when necrosis was walled-off [11].
The prognostic value of adipokines in the prediction of
the development of pancreatic necrosis, severe course of
the disease, need for surgical intervention and mortality
were the primary outcome measures in this study. The
development of peripancreatic necrosis was the secondary
measure.
Blood samples
Peripheral blood samples from AP patients were ob-
tained at the day of the admission and after 48–72 h
(3rd day). The blood samples of the control group were
obtained only once. All the samples were centrifuged and
stored at −20 °C until analysis. Blood sample analysis was
performed at the Center of Laboratory Medicine, Vilnius
University. Adipokines and IL-6 serum concentrations were
measured using ELISA kits (DIAsourceImmunoAssays SA/
Adiponectin, IBL/International Leptin Elisa, DIAsource-
ImmunoAssays SA/Resistin ELISA, BioVendor Human
Visfatin (Nampt) ELISA and DIAsourceImmunoAssays
SA/IL6) according to the manufacturer’s instructions.
Compact microplate processor Gemini (Stratec Biomedical
AG) was used. Plasma levels of CRP and other tests were
measured in accordance with hospitals laboratory routine.
CT scan
Contrast enhanced CT (CECT) scans were performed
for patients with acute pancreatitis no earlier than the
3rd day and no later than the 7th day after the onset of
symptoms. All CECT examinations were performed in
four centers:
1. Vilnius University Hospital “Santariskių Klinikos”
2. Vilnius City Clinical Hospital
3. Republican Vilnius University Hospital
4. Hospital of the Lithuanian University of Health
Sciences “Kauno Klinikos”
All examinations were performed on multidetector CT
scanners (GE VCT, GE Light Speed Pro and ToshibaAquilion) and covered abdominal region and pelvic re-
gion, if required. Standard pancreatic scanning protocol
was used with late arterial and portovenous phases. CT
scans were retrospectively and independently reviewed on
workstations (GE Advanced WorsktationVolumeShare 5
(AW4.6)) by two experienced abdominal radiologists who
were unaware of presenting signs and symptoms or of
patient outcomes. Each case was independently assessed
by both observers using the modified CT severity index
(MCTSI). Possible pancreatic necrosis and their extent,
peripancreatic fluid collections and extrapancreatic find-
ings (pleural effusion, ascites, parenchymal, vascular and
GI tract complications) were evaluated. In the cases of dis-
agreement of indexes between two radiologists consensus
was reached after secondary review of CT scans by the
same radiologists and discussion. Up to three biggest peri-
pancreatic fluid collections were measured in three per-
pendicular dimensions (in cm). The simplified formula of
an ellipsoid was used (length x width x thickness/2) to
calculate the volume of the peripancreatic fluid collec-
tions. This formula enables quick and easy calculation of
the volume and is widely used in radiology [25–27].
Statistical analysis
Statistical analysis was performed using R v. 3.2.0 package.
Categorical variables were expressed as absolute numbers
and percent. For the association between two variables
Pearson's chi-square test or Fisher's exact test were applied,
as appropriate. Continuous variables were expressed as
mean ± standard deviation (SD) and median ± interquartile
ranges (IQR). Normality of the variables was checked by
Shapiro-Wilk statistic. All variables, except age, were not
distributed according to the normal distribution; therefore
nonparametric hypotheses were tested to detect significant
differences between selected categories. ROC curves, area
under the curve (AUC) and optimal cut off values were
calculated using R plugin pROC [28]. AUC was calculated
using the 95 % confidence interval (CI). A p value less than
0.05 was considered statistically significant.
Results
Patients’ characteristics
During the study period 119 of AP patients were pro-
spectively assessed for possible inclusion in the study.
Seventeen patients were excluded for various reasons
(Fig. 1). In the final analysis 102 of AP patients (50 males
and 52 females, mean age 55.7 ± 18.1 years) were in-
cluded. Mean time after onset of the symptoms was
20.3 ± 13.8 h. The main etiological factors of AP were
biliary stones (42.2 %) and alcohol (35.3 %). Necrosis of
the pancreas during CECT was detected in 60 (58.8 %)
patients and the peripancreatic necrosis was present in
67 (65.7 %) cases. Ninety two (90.2 %) patients were
treated conservatively and 10 (9.8 %) underwent the





















Fig. 1 The flowdiagram for patient’s selection. Abbreviations:
CT – Computed Tomography; AP – Acute Pancreatitis; MAP – Mild
Acute Pancreatitis; MSAP - Moderately severe acute pancreatitis;
SAP – Severe Acute Pancreatitis




Severe AP P value*
(n = 82) (n = 20)
Age 55.90 ± 19.02 55.00 ± 14.20 0.814
Sex
Male (%) 38 (46.3) 12 (60.0)
Female (%) 44 (53.7) 8 (40.0)
BMI 27.99 ± 7.54 31.07 ± 10.02 0.041
Adiponectin
μg/ml (1st day)
11.10 ± 9.58 7.91 ± 10.07 0.446
Adiponectin
μg/ml (3rd day)
10.04 ± 9.14 8.64 ± 6.44 0.870
Leptin ng/ml
(1st day)
7.21 ± 11.83 4.17 ± 8.14 0.397
Leptin ng/ml
(3rd day)
2.33 ± 3.85 0.84 ± 6.03 0.533
Visfatin ng/ml
(1st day)
4.15 ± 5.45 5.42 ± 4.74 0.179
Visfatin ng/ml
(3rd day)
2.94 ± 4.58 7.34 ± 5.68 0.059
IL-6 pg/ml
(1st day)
133.00 ± 350.47 635.95 ± 634.45 0.000
IL-6 pg/ml
(3rd day)
94.97 ± 323.86 545.31 ± 574.17 0.000
Resistin ng/ml
(1st day)
10.70 ± 8.65 20.20 ± 31.75 0.000
Resistin ng/ml
(3rd day)
11.67 ± 14.87 40.75 ± 28.27 0.000
CRP mg/ml
(1st day)
9.54 ± 64.79 16.15 ± 74.86 0.220
CRP mg/ml
(3rd day)
180.30 ± 224.87 377.13 ± 91.39 0.000
SOFA (1st day)
(score)
1 ± 2 3 ± 3 0.000
SOFA (3rd day)
(score)
1 ± 2 4 ± 2 0.000
MCTSI (score) 6 ± 4 8 ± 2 0.000
Pancreatic
necrosis (%)




31.50 ± 518.50 (48) 731.00 ± 2141.50 (19) 0.000
Need for
surgery (%)
2 (2.4) 8 (40.0) 0.000
Hospital stay (d) 11.00 ± 7.00 30 ± 22.75 0.000
Number of
deaths (%)
0 (0.0) 5 (25.0) 0.000
Abbreviations: AP Acute Pancreatis, BMI Body Mass Index, IL-6 Interleukin-6,
CRP C-Reactive Protein, SOFA The Sequential Organ Failure Assessment score,
MCTSI Modified Computed Tomography Severity Index
Age was expressed as mean ± standard deviation (SD); sex, pancreatic necrosis,
need for surgery and number of deaths by percents, other variables - as
median ± interquartile ranges (IQR)
*Significant in bold
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one case (10.0 %), four patients (40.0 %) underwent only
open necrosectomy and the last five operated patients
got combined interventions (50.0 %); Mean length of
hospital stay was 20.8 ± 28.3 days. Five patients died dur-
ing hospitalization (mortality rate – 4.9 %).
According to the revisited Atlanta classification, based
on organ failure, 27 (26.5 %) of all patients had mild,
55 (53.9 %) - moderately severe, and 20 (19.6 %) - severe
AP (Fig. 1). The main differences in the clinical and bio-
chemical characteristics between SAP and milder forms of
the AP are shown in Table 1.
Forty healthy persons were included as a control
group: 17 males and 23 females with the mean age of
54.3 ± 16.1 years and BMI of 27.9 ± 4.7 kg/m2. No sig-
nificant differences were noted between the AP patients
and control group in terms of their gender, age or BMI.
Serum resistin, visfatin and IL-6 values are significantly
higher in AP patients than in controls
Median admission serum adiponectin levels were higher in
AP group (median 10.7 μg/ml, Q1-Q3 6.8–16.8 μg/ml) than
in controls (median 8.3 μg/ml, Q1-Q3 5.6–12.3 μg/ml),
p > 0.05. Median admission serum leptin levels were higher
in AP group (median 6.7 ng/ml, Q1-Q3 2.8–14.5 ng/ml)
than in controls (median 4.0 ng/ml, Q1-Q3 1.5–8.5 ng/ml),
p > 0.05. Median admission serum resistin levels were
higher in AP group (median 12.6 ng/ml, Q1-Q3 7.4–
18.2 ng/ml) than in controls (median 5.4 ng/ml, Q1-Q3
4.5–6.7 ng/ml), p < 0.05. Median admission serum visfatin
levels were higher in AP group (median 4.7 ng/ml, Q1-Q3
2.1–7.4 ng/ml) than in controls (median 1.6 ng/ml, Q1-Q3
1.2–2.2 μg/ml), p < 0.05. Median admission serum IL-6
levels were higher in AP group (median 194,3 pg/ml,
Q1-Q3 39,8–508,8 pg/ml) than in controls (median
1.5 pg/ml, Q1-Q3 0.3–7.0 pg/ml), p < 0.05.
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severity in AP
Median admission and 3rd day resistin, IL-6 and 3rd day
CRP values were significantly higher in SAP group when
compared with other patients. No significant differences
were noted for admission and 3rd day adiponectin,
leptin, visfatin and admission CRP values between SAP
and other patients (Table 1). The ROC analysis applied
for early SAP prediction showed significant results only
for admission resistin and IL-6 (Fig. 2). The detail results
are presented in Table 2.
Admission adipokine levels can’t predict development of
necrosis, need for interventions and mortality
The ROC analysis applied to predict the development of
necrosis on admission showed no significant results for
adipokines. Only admission IL-6 with a cut-off 157.0 pg/ml
could be used for early prediction of necrosis (sensitivity
75.0 %, specificity 67.1 %, AUC 0.72). The ROC ana-
lysis applied to predict the need for interventions and
mortality on admission also showed no statistically
significant results.
The peripancreatic necrosis is associated with the
development of SAP
Median volume of the peripancreatic necrosis was lower
in mild and moderately severe AP (median 31.5 ml,
Q1-Q3 0–518.5 ml) than in SAP (median 731.0 ml,
Q1-Q3 432.5–2574.0 ml), p < 0.05. The analysis of the
ROC curves demonstrated, that the cut-off value of
112.5 ml is associated with SAP (sensitivity 61.0 %, specifi-
city 95.0 %, AUC 0.80) and 433.0 ml cut-off value is asso-
ciated with the need of intervention (sensitivity 68.5 %,
specificity 100 %, AUC 0.87).Fig. 2 Prognostic value of admission resistin and IL-6 levels for
development of SAP. IL-6 cut-off value 473.4 pg/ml predicts SAP
(sens. 82.9 %, spec. 75.0 %, PPV 51.7 %, NPV 93.2 %, AUC 0.78).
Resistin cut-off value 13.7 ng/ml predicts SAP (sens. 63.4 %, spec. 80.0 %,
PPV 34,8 %, NPV 92,9 %, AUC 0.76). Abbreviations: IL-6 – Interleukin-6;
AUC - area under the curveDiscussion
According to the revised Atlanta 2012 classification
diagnosis of SAP is based on organ failure and can be
determined only after 48 h from admission [14]. These
2 days can be fatal for the AP patient, so early prediction
of SAP remains very important. Optimal marker should
help to separate the milder forms of the disease from se-
vere ones even on admission. So, all previously published
results about prognostic possibilities of the different
markers after 48 h from admission are not clinically im-
portant and we need to focus only on the 1st day data.
Only the early predictor could help to make the decision
about the patient’s needs to be transferred to the high
volume center timely, enteral nutrition and maybe
prophylactic administration of antibiotics use in early
phase of AP.
Prognostic value of adipokines in AP patients has been
noticed some years ago. Experimental studies with rats
started in 2002 and demonstrated significant differences
of leptin concentrations between AP patients and con-
trols, and between acute edematous and acute necrotiz-
ing pancreatitis groups [29–31]. Although in some other
clinical studies the prognostic value of leptin on pan-
creatic necrosis was proven [23], according to our data
leptin is not suitable for predicting SAP, development of
necrosis, need for interventions and mortality. However,
this data replicates the results of some previously pub-
lished studies [24, 32, 33].
Only one study published in 2009 has shown adipo-
nectin to be a valuable prognostic marker of the SAP,
whereas, serum adiponectin levels from 1st to 3rd day
were significantly lower for patients with SAP than for
those with MAP [19]. According to our data and other
studies, adiponectin is also not a good marker for the
prediction of AP course [33]. There was no significant
difference of adiponectin concentrations even between
the AP patients and the healthy controls in our study.
Some promising results related to the resistin and vis-
fatin prognostic value were published in 2007–2011 by
Shaffler’s group [20–22]. This study has shown that both
adipokines concentrations had significant differences be-
tween MAP and SAP groups, they correlate with severity
of disease, need for interventions and outcome. Resistin
and visfatin are also good markers for peripancreatic ne-
crosis. The cut-off values of 11.9 ng/ml and 1.8 ng/ml
respectively allows the higher ranges of radiological
scores prediction. These results are consistent with an-
other study, published in 2010, which demonstrates, that
both adipokines may be possibly used for AP prognosis
and disease monitoring [34].
Despite the above mentioned data, our results on vis-
fatin did not meet the expectations. The admission levels
of visfatin hasn’t shown any significant value for pre-
dicting the development of SAP or necrosis, need for
Table 2 Admissions levels of resistin and IL-6 as predictors of SAP
AUC 95 % CI Cut-off Sens., % Spec., % PPV NPV
IL-6 Admission 0.78 0.6596–0.9075 473.4 82.9 75.0 51.7 93.2
IL-6 3rd day 0.82 0.7322–0.9117 119.9 54.9 100.0 35.1 100.0
Resistin Admission 0.76 0.6462–0.8782 13.7 63.4 80.0 34.8 92.9
Resistin 3rd day 0.89 0.8232–0.9597 23.9 79.3 85.0 50.0 95.6
CRP Admission 0.59 0.4542–0.7238 4.4 35.4 90.0 25.4 93.5
CRP 3rd day 0.79 0.6932–0.8873 301.1 70.7 80.0 40.0 93.5
Abbreviations: IL-6 Interleukin-6, AUC area under the curve, CI confidence interval, Sens sensitivity, Spec specificity, PPV positive predictive value, NPV negative
predictive value
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differences of visfatin concentrations between AP and
healthy controls were observed during the study.
Interestingly, we observed the statistically significant
differences of admission resistin concentrations between
all compared groups. The cut-off value of 13.7 ng/ml
predicts SAP (sensitivity 63.4 %, specificity 80.0 %, AUC
0.76) on admission. This is consistent with the results
presented by Schaffler group which demonstrated that
admission resistin cut-off value of >11.9 ng/mL can serve
as a positive predictor of a Balthazar score >3 and Necrosis
score >2 [21]. Compared to the last published meta-
analysis and other publications on BISAP (cut-off ≥3, sensi-
tivity 51–62 %, specificity 72–91 %, AUC 0.74–0.87) and
APACHE II (cut-off ≥8, sensitivity 81–83 %, specifi-
city 59–66 %, AUC 0.78–0.82) scores, the result of resistin
as a single predictor for SAP is acceptable [35, 36]. Never-
theless, it is not as universal as IL-6, which according to
our data can predict SAP on admission with the cut-off
473,4 pg/ml (sensitivity 82,9 %, specificity 75,0 %, AUC
0,78) as well as necrosis (cut-off 157.0 pg/ml, sensitivity
75.0 %, specificity 67.1 %, AUC 0.72). Our cut-off value of
IL-6 as the predictor of SAP is similar to the results of
Nieminem group published in 2014 (cut-off 501.6 pg/ml,
sensitivity 48.0 %, specificity 93.5 %, AUC 0.81) [37].
Though, much lower cut-off values of IL-6 for prediction
of necrosis are demonstrated by the other authors – in the
range of 50–83.3 pg/ml (with sensitivity 84–94 %, specifi-
city 72–73 %, AUC 0.79–0.86) [38, 39]. The discrepancy
between earlier published studies and our own results
could be explained by the fact that the other researchers
assessed only the necrosis of pancreas and didn’t assess
the peripancreatic necrosis as the possible source of in-
flammatory cytokines. The data from other authors and
our results show the importance of the peripancreatic ne-
crosis in pathogenesis of SAP [17].
Our study has shown that the value of adipokines in
predicting the course and outcome of AP was rated too
good. Only resistin can be used for early AP course pre-
diction. The value of peripancreatic necrosis, as the
main possible source of resitin in the course of AP
haven’t been studied enough. According to our data even112.5 ml volume of peripancreatic necrosis is associated
with SAP (sensitivity 61.0 %, specificity 95.0 %, AUC 0.80).
Similar results comes from Meyrignac group study [17].
Although peripancreatic necrosis is assessed only on CT
scan and it’s prognosis on AP course is too late, surgeons
should be interested in a fact, that 433.0 ml cut-off value
of the peripancreatic necrosis is associated with a greater
need for intervention (sensitivity 68.5 %, specificity 100 %,
AUC 0,87). So there is a great stimulus to initiate a new
study trying to find the relationship between resistin, peri-
pancreatic necrosis, acute pancreatitis course, complica-
tions and outcomes.
Despite the large amount of prognostic AP studies,
optimal early marker has not been found yet. Probably
no physician would send the AP patient to intensive care
unit or other specialized center without other clinical
findings based only on the high concentrations of the
prognostic markers. Errors in assessing the AP patient’s
condition in early phase could be dramatic. That is why
the evaluation of the AP patient’s status must be com-
plex and based on revised Atlanta classification recom-
mendations, prognostic markers, scores and, of course,
on each physician’s clinical experience.
Study limitations
Like many other studies focusing on the research of the
prognostic biochemical markers our study also has some
methodological and technical limitations. Although the
study was multicenter, the number of patients in SAP
group was significantly lower than in MAP +MSAP
group. From 102 included AP patients only 20 had the
severe course of the disease. Therefore, the relatively
small number of patients with SAP was compared to the
group of 82 patients with MAP and MSAP.
Because of the conservative treatment strategy of AP
in last decade the number of interventions and deaths
decreased significantly. In our cohort, 10 out of 102 pa-
tients required interventional treatment and five patients
died during the hospitalization. The lack of the patients
was the reason that we couldn’t separate AP by the type
of the necrosis. Only three patients had pancreatic ne-
crosis without signs of peripancreatic necrosis. Another
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tween acute peripancreatic fluid collection and acute
necrotic collection in the 1st week of AP. A diagnosis of
peripancreatic necrosis based CECT findings often can-
not be made specifically but can be suspected when
slightly heterogeneous peripancreatic collections are
seen. After 1 week from onset, the collection usually be-
comes clearly heterogeneous, and peripancreatic necro-
sis can be diagnosed on CECT images.
As several previously published studies report, adipo-
kines have a good predictive value for the AP course of
population with obesity. In this study we also tried to
divide AP patients according to their BMI, but the
groups were not homogenic and the number of patients
in some groups was not satisfactory for analysis. So, for
now we could not assess adipokines in predicting sever-
ity and outcome of AP among people suffering from
obesity. Of course, this kind of investigation could be
useful in routine clinical practice for the prediction of
AP course and outcome among high risk (high BMI) pa-
tients. That is why we’ll try to accomplish this idea in
the future with sufficient number of patients.
Conclusions
Resistin and IL-6 cut-off values 13.7 ng/ml and
473.4 pg/ml could be used as an early markers of severe
AP as well as the peripancreatic necrosis volume of
112.5 ml. The IL-6 cut-off value 157.0 pg/ml predicts
necrosis and 433.0 ml cut-off value of peripancreatic
necrosis is associated with a greater need for intervention.
There is no optimal early marker for AP severity
stratification yet. The evaluation of the AP patient’s sta-
tus at first few hours after admission must be complex
and only then the right decision could be made.
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